• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glytec raises $21M for insulin dosing management tech

April 26, 2021 By Sean Whooley

GlytecGlytec announced today that it raised $21 million in financing to fund its glycemic management technology.

Waltham, Mass.-based Glytec received $9 million in debt financing from Silicon Valley Bank, combined with $12 million in equity funding, led by Savitr with contribution from other private investors, according to a news release.

The company said it plans to use the funds to continue research and development around patient safety, provider workflows and analytics for its eGlycemic Management System (eGMS) for managing insulin. Additionally, funds are earmarked to adding talent to the workforce and enhancing integrations with electronic health records (EHRs), mobile apps and other diabetes care technologies ranging across the continuum of care.

Glytec launched the eGMS last month. It is centered around the FDA-cleared Glucommander software, which uses real-time and historical data to recommend insulin dosing by learning each patient’s insulin sensitivity and anticipating future needs. The ensuing personalized treatment regime can reduce hypoglycemia, hyperglycemia, lengths of stay, readmissions and cost of care.

“Hospitals have always been structured to treat acute conditions and providers generally segment and focus on what they deem is most critical for each patient, with limited collaboration across disciplines. This approach doesn’t account for the fact that a patient’s blood glucose is an underlying factor that impacts nearly every condition in every department of the hospital,” Glytec president & CEO Ed Furlong said in the release. “With a growing shortage of endocrinologists, there’s no way they can scale to be at every bedside. Glucommander’s personalized dosing decision support helps them scale efforts. With the funding from SVB and Savitr, and the exceptional support we’re getting from their teams, we’re ready to help more hospitals improve outcomes and the patient care they provide.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Glytec

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS